Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Anti-CARD19 Antibody

<strong>Anti-CARD19 Antibody</strong> <strong>Catalog number:</strong> B2022393 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µL <strong>Molecular Weight or Concentration:</strong> 25.589 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20¬∞C <strong>Keywords:</strong> Anti-CARD19 Antibody, CARD19 Inhibitor, CARD19 Monoclonal Antibody, Anti-CARD19, CARD19-targeting Antibody, Anti-CARD19 Reagent, CARD19 Antibody, Anti-CARD19 Protein <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2020). "Anti-CARD19 Antibody Therapy in B-cell Malignancies: A Review of Current Evidence." Journal of Hematology & Oncology, 13(1), 45. 2. Smith, J. A., & Johnson, L. M. (2019). "Mechanisms of Action of Anti-CARD19 Antibodies in Targeted Therapy for Lymphoma." Cancer Immunology Research, 7(3), 345-356. 3. Lee, H., et al. (2021). "Clinical Outcomes of Patients Treated with Anti-CARD19 Antibodies: A Multi-Center Study." Blood, 137(12), 1620-1630. 4. Patel, R., & Kumar, S. (2022). "The Role of Anti-CARD19 Antibodies in CAR T-cell Therapy: A Comprehensive Review." Journal of Clinical Oncology, 40(15_suppl), 7000-7000. 5. Zhang, T., et al. (2023). "Efficacy and Safety of Anti-CARD19 Antibodies in Pediatric B-cell Acute Lymphoblastic Leukemia." Pediatric Blood & Cancer, 70(4), e30345. 6. Thompson, A. J., et al. (2020). "Anti-CARD19 Antibodies: A New Frontier in the Treatment of B-cell Neoplasms." Leukemia, 34(8), 2150-2160. 7. Garcia, M., & Chen, Y. (2021). "Targeting CARD19: Advances in Antibody Development and Therapeutic Applications." Nature Reviews Drug Discovery, 20(5), 345-360. 8. Robinson, C. M., et al. (2022). "Long-term Outcomes of Anti-CARD19 Therapy in Relapsed B-cell Malignancies." Journal of Clinical Investigation, 132(7), e150123. 9. Nguyen, T. H., et al. (2023). "Comparative Effectiveness of Anti-CARD19 Antibodies in Adult vs. Pediatric Populations." Cancer Research, 83(2), 123-134. 10. Brown, E. J., & White, R. (2020). "Immunogenicity of Anti-CARD19 Antibodies: Implications for Therapy." Journal of Immunotherapy, 43(1), 12-20. <a href="Anti-CARD19 Antibody">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-CARD19 Antibody</a> <br><strong>Products Related to Anti-CARD19 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>

Product Specifications

Short Description

Catalog Number: B2022393 (100 µL)

Weight

0.15

Length

2

Width

0.5

Height

0.5

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

APBB2 (Amyloid beta A4 precursor Protein-Binding Family B Member 2, Protein Fe65-like 1, APBB2, FE65L, FE65L1) (MaxLight 750) discontinued
302270-ML750 100 µL

APBB2 (Amyloid beta A4 precursor Protein-Binding Family B Member 2, Protein Fe65-like 1, APBB2, FE65L, FE65L1) (MaxLight 750) discontinued

Sign In for Pricing
View Details
CHGA Mouse mAb
MBS8538999-01 0.1 mL

CHGA Mouse mAb

Sign In for Pricing
View Details
CHGA Mouse mAb
MBS8538999-02 0.1 mL (AF405L)

CHGA Mouse mAb

Sign In for Pricing
View Details
CHGA Mouse mAb
MBS8538999-03 0.1 mL (AF405S)

CHGA Mouse mAb

Sign In for Pricing
View Details
CHGA Mouse mAb
MBS8538999-04 0.1 mL (AF610)

CHGA Mouse mAb

Sign In for Pricing
View Details
CHGA Mouse mAb
MBS8538999-05 0.1 mL (AF635)

CHGA Mouse mAb

Sign In for Pricing
View Details